222 BERKELEY STREET, BOSTON, MA
Financial Results, Reg. FD, Other Events
Annual Meeting of Stockholders Held; 64.1 Million Votes Cast
Investor Presentation
Reports First Quarter 2026 Financial Results and Business Update
Annual Report to Security Holders
Announces Changes to Board of Directors
Receives Positive CHMP Opinion for IMCIVREE® (setmelanotide) for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity due to Hypothalamic Injury or Impairment
Q2
Q1
FY 2025
Q3
FY 2023
Registration Statement for Securities to be Offered to Employees
S-3ASR
Prospectus filed pursuant to Rule 424(b)(5)
Additional Proxy Materials
Definitive Proxy Statement
PRE 14A
Statement of Changes in Beneficial Ownership
Initial Statement of Beneficial Ownership
Notice of Proposed Sale of Securities